News | Stents Bioresorbable | March 11, 2016

Magnesium Elektron, Biotronik Partner to Develop Bioresorbable Alloy System

Ten-year research program led to development of SynerMag bioresorbable magnesium coronary scaffold

Biotronik, Magnesium Elektron, bioresorbable magnesium coronary scaffold, partner

Specially designed extrusion equipment at Magnesium Elektron’s purpose-built facility in England produces wire made from SynerMag bioresorbable magnesium alloy. Photo courtesy of Business Wire.

March 11, 2016 — Magnesium Elektron, developer, manufacturer and supplier of high-performance magnesium alloys, announced that Biotronik has been its partner in the development of its SynerMag bioresorbable magnesium alloys for cardiovascular application.

The two companies entered into a joint research and development program in 2006 aimed at developing a bioresorbable magnesium coronary scaffold. The ten-year research program has resulted in Elektron’s SynerMag 410 alloy system being used as the platform material in the Biotronik Magnesium Scaffold, what the company calls the world’s first clinically proven magnesium-based bioresorbable scaffold.

The latest generation Biotronik Magnesium Scaffold was clinically evaluated in the recent BIOSOLVE II study. The clinical data from BIOSOLVE II will be used to obtain CE approval for the device, and the release of the data was accompanied by publication in The Lancet.

Production of Elektron’s SynerMag 410 alloy system takes place in a new purpose-built manufacturing and testing facility in Manchester, United Kingdom. The facility, which achieved ISO 13485 approval in 2014, ensures Biotronik has a facility in its supply chain that will directly support its own production activities for the Biotronik Magnesium Scaffold.

For more information:,

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init